Stock Markets

Daily coverage of equity markets, sectors, and major indices.

In-depth reporting on U.S. and global stock markets, including index performance, sector rotation, earnings reactions, volatility trends, and notable single-stock moves. Designed to help traders and investors understand what is driving price action across equities.

Articles

23,620 total articles

Markets Gain as Supreme Court Ruling Dampens Tariff Fears; Nvidia Earnings Take Center Stage

Markets Gain as Supreme Court Ruling Dampens Tariff Fears; Nvidia Earnings Take Center Stage

U.S. equity benchmarks closed higher on Friday after the Supreme Court curtailed much of President Trump's tariff program, a move that could ease cost pressures for businesses. The S&P 500, Nasdaq and Dow all posted gains for the day and week, while attention shifts to Nvidia's upcoming earnings and a docket of economic reports due in the coming da…

MoonLake Shares Rise After Positive Phase 2 axSpA Data for Sonelokimab

MoonLake Shares Rise After Positive Phase 2 axSpA Data for Sonelokimab

MoonLake Immunotherapeutics saw its stock climb in premarket trading after disclosing topline results from the Phase 2 S-OLARIS study of sonelokimab in axial spondyloarthritis (axSpA). The data showed high rates of clinical response at Week 12, corroborated by PET and MRI imaging, while the safety profile remained consistent with earlier studies. T…

Vertical Aerospace Shares Slip After Raymond James Lowers Rating

Vertical Aerospace Shares Slip After Raymond James Lowers Rating

Vertical Aerospace (NYSE: EVTL) shares fell 2.7% in premarket trading after Raymond James downgraded the stock from Market Perform to Underperform. Analyst Savanthi Syth pointed to concerns about the company’s financial runway, competitive pressure from rivals, and potential talent losses, while noting the company is seeking an industrial partner t…

Mizuho Upgrade Boosts Acadia Shares on Remlifanserin Prospects

Mizuho Upgrade Boosts Acadia Shares on Remlifanserin Prospects

Acadia Pharmaceuticals shares rose 1.9% in premarket trading after Mizuho analyst Uy Ear upgraded the stock from Neutral to Outperform and lifted the price target to $35.00 from $29.00. The upgrade reflects a view that remlifanserin (ACP-204), Acadia’s Phase 2 candidate in the RADIANT trial for Alzheimer’s disease psychosis, is undervalued, and tha…

BofA Flagged Elevated CTA Unwind Risk Despite Recent Rally

BofA Flagged Elevated CTA Unwind Risk Despite Recent Rally

Bank of America analysts say recent market strength has provided some relief for trend-following funds, but positioning remains stretched and the risk of a commodity trading advisor (CTA) unwind is still elevated. Systematic strategies could sell materially in a down market, with estimates as high as $132 billion across models and up to $95 billion…

Hamborner REIT narrows office exposure, issues 2026 FFO and rent guidance

Hamborner REIT narrows office exposure, issues 2026 FFO and rent guidance

Hamborner REIT AG has revised its portfolio composition to materially reduce office weighting and provided guidance for the 2026 financial year, forecasting funds from operations (FFO) between €38.0 million and €42.0 million and expected rental income of €87.5 million to €89.5 million. The firm attributes a projected decline in rental receipts to p…

Citi Stays Bullish on Equities After Strong Q4 Results and Stable Estimates

Citi Stays Bullish on Equities After Strong Q4 Results and Stable Estimates

Citi told clients that fourth-quarter results and steady consensus estimates underpin its optimistic outlook for 2026. Analyst Scott Chronert reiterated that the firm "maintains a constructive fundamental outlook for 2026," citing positive Q4 2025 earnings trends, accelerating sales across market caps and an above-consensus S&P 500 earnings project…